“…Alteration of ETs has been demonstrated in both type I and type II diabetes (Bertello et al, 1994;De Mattia et al, 1998;Donatelli et al, 1994;Haak et al, 1992;Kamoi et al, 1994;Kawamura et al, 1992;Laurenti et al, 1997;Letizia et al, 1997;Morise et al, 1995;Takahashi et al, 1990). Although, a number of studies can be cited that provide contradictory reports of plasma ET levels in diabetic patients, it should be noted that these peptides act in both an autocrine and paracrine fashion.…”